首页> 外文期刊>Neuro-Oncology >HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood-tumor barrier penetration unlinked to a passive marker
【24h】

HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood-tumor barrier penetration unlinked to a passive marker

机译:HER2抗体 - 药物缀合物对血源性异种移植模型中的乳腺癌脑转移的生长控制,具有非均相的血液肿瘤阻隔渗透,而不是被动标记

获取原文
获取原文并翻译 | 示例
       

摘要

Background. Brain metastases of HER2+ breast cancer persist as a clinical challenge. Many therapeutics directed at human epidermal growth factor receptor 2 (HER2) are antibodies or antibody-drug conjugates (ADCs), and their permeability through the blood-tumor barrier (BTB) is poorly understood. We investigated the efficacy of a biparatopic anti-HER2 antibody-tubulysin conjugate (bHER2-ATC) in preclinical models of brain metastases.Methods. The compound was evaluated in 2 hematogenous HER2+ brain metastasis mouse models, SUM190-BR and JIMT-1-BR. Endpoints included metastasis count, compound brain penetration, cancer cell proliferation, and apoptosis.Results. Biparatopic HER2-ATC 3 mg/kg prevented metastasis outgrowth in the JIMT-1-BR model. At 1 mg/kg bHER2-ATC, a 70% and 92% reduction in large and micrometastases was observed. For the SUM190-BR model, an 85% and 53% reduction, respectively, in large and micrometastases was observed at 3 mg/kg, without statistical significance. Proliferation was reduced in both models at the highest dose. At the endpoint, bHER2-ATC uptake covered a median of 4-6% and 7-17% of metastasis area in the JIMT-1-BR and SUM190-BR models, respectively. Maximal compound uptake in the models was 19% and 86% in JIMT-1-BR and SUM190-BR, respectively. Multiple lesions in both models demonstrated ADC uptake in the absence or low diffusion of Texas Red Dextran, a marker of paracellular permeability. Using in vitro BTB assays, the ADC was endocytosed into brain endothelial cells, identifying a potentially new mechanism of antibody permeability.Conclusions. Biparatopic HER2-ATC significantly prevented JIMT-1-BR brain metastasis outgrowth and showed activity in the SUM190-BR model. The bHER2-ATC penetration into metastases that are impermeable to fluorescent dye suggested an endocytic mechanism of brain penetration.
机译:背景。 ER2 +乳腺癌的脑转移持续存在于临床挑战。许多针对人表皮生长因子受体2(HER2)的治疗剂是抗体或抗体 - 药物缀合物(ADC),并且它们通过血肿瘤屏障(BTB)的渗透性较差地理解。我们研究了双层抗HER2抗体 - 管蛋白缀合物(BHER2-ATC)在脑转移的临床前模型中的疗效。方法。该化合物在2个血液源性HEL2 +脑转移小鼠模型中评价,SUM190-BR和JIMT-1-BR。终点包括转移计数,复合脑渗透,癌细胞增殖和凋亡。结果。 Biparopic Her2-ATC 3 Mg / kg防止JIMT-1-BR模型中的转移性过度。在1mg / kg bher2-ATC下,观察到70%和92%的大和微转移减少。对于SUM190-BR模型,分别在3mg / kg的情况下观察到大而微量酶的85%和53%,无统计学意义。在最高剂量的两种模型中降低了增殖。在端点,BHER2-ATC吸收分别在JIMT-1-BR和SUM190-BR模型中覆盖了4-6%和7-17%的转移区域。模型中的最大化合物摄取分别为Jimt-1-BR和Sum190-Br中的19%和86%。两种模型中的多个病变在德克萨斯红葡聚糖的缺失或低扩散中显示出ADC吸收,这是阴茎渗透性的标志物。使用体外BTB测定,ADC被联核化成脑内皮细胞,鉴定抗体渗透性的潜在新机制。结论。 Biparatopic HER2-ATC显着防止了JIMT-1-BR脑转移的过度生长,并在SUM190-BR模型中显示了活性。骨髓2-ATC渗透到荧光染料不透水的转移方案表明脑渗透的内吞机制。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号